Showing 1 - 8 results of 8 for search 'Joon-young Hur', query time: 0.04s Refine Results
  1. 1
    Sustainable Development Trend of Chinese Advertising Design from 1992 to 2020: A Bibliometric and Content Analysis

    Sustainable Development Trend of Chinese Advertising Design from 1992 to 2020: A Bibliometric and Content Analysis by Rui-zhi Zhang, Joon-young Hur

    Published 2022-10-01
    Get full text
    Article
  2. 2
    Olaratumab and doxorubicin for the treatment of metastatic soft tissue sarcoma: a retrospective case series

    Olaratumab and doxorubicin for the treatment of metastatic soft tissue sarcoma: a retrospective case series by Joon Young Hur, Se Hoon Park, Su Jin Lee

    Published 2019-06-01
    Get full text
    Article
  3. 3
    Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma

    Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma by Joon Young Hur, Bo Mi Ku, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Myung-Ju Ahn

    Published 2022-01-01
    Get full text
    Article
  4. 4
    Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma.

    Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma. by Joon Young Hur, Bo Mi Ku, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Myung-Ju Ahn

    Published 2022-01-01
    Get full text
    Article
  5. 5
    Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience

    Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience by Joon Young Hur, Ji-Yeon Kim, Jin Seok Ahn, Young-Hyuck Im, Jiyun Lee, Minsuk Kwon, Yeon Hee Park

    Published 2020-05-01
    Get full text
    Article
  6. 6
    Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study

    Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study by Seonggyu Byeon, Hyera Kim, Jinchul Kim, Minsuk Kwon, Joon Young Hur, Hwang Gyun Jeon, Seong Soo Jeon, Hyun Moo Lee, Se Hoon Park

    Published 2020-11-01
    Get full text
    Article
  7. 7
    Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment

    Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment by Kyung Hwan Kim, Joon Young Hur, Jinhyun Cho, Bo Mi Ku, Jiae Koh, June Young Koh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn, Eui-Cheol Shin

    Published 2020-01-01
    Get full text
    Article
  8. 8
    Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

    Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients by Steven M. Bray, Jeeyun Lee, Seung Tae Kim, Joon Young Hur, Philip J. Ebert, John N. Calley, Isabella H. Wulur, Thejaswini Gopalappa, Swee Seong Wong, Hui-Rong Qian, Jason C. Ting, Jiangang Liu, Melinda D. Willard, Ruslan D. Novosiadly, Young Suk Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Amit Aggarwal, Hee Cheol Kim, Christoph Reinhard

    Published 2019-10-01
    Get full text
    Article

Search Tools: